Yang Liu obtained her M.D. in the School of Medicine, Xi’an Jiaotong University in China, and got a M.Sc. degree in Microbiology and Immunology. She joined Dr. Michael Fehlings’ lab in April 2000, and was assigned as the lab manager in the year of 2002.
Apart from maintaining daily laboratory operation and coordination, Yang participated in several different projects for the development of novel neuroprotective strategies to repair the spinal cord. As a senior technician, she has extensive experiences with hands-on technical skills in cellular and molecular biology.
Yang contributes in lab training programs for graduate students by providing technical support and supervising summer students with projects. Yang’s main project, titled “An engineered transcription factor which activates VEGF-A enhances recovery after spinal cord injury,” has been published in 2010 by Neurobiology Disease. Her current research theme is to evaluate the therapeutic effects of a novel self-assembling peptide (SAP QL6) to promote repair and regeneration of the injured spinal cord.
The preliminary results have shown that SAP QL6 led to a significant reduction in post-traumatic apoptosis, inflammation and astrogliosis. These neuroanatomical improvements were associated with significant neurobehavioral recovery. As the first detailed examination of the pathophysiological bases of QL6 in SCI, this work highlights the therapeutic potentials of the SAP in this devastating disorder and other forms of CNS injury.